Trigonal Planar Heteroleptic Lanthanide(III) Bis(silyl)amide Complexes Containing Aminoxyl Radicals and Anions.

Modulation of the crystal field (CF) in lanthanide (Ln) complexes can enhance optical and magnetic properties, and large CF splitting can be achieved with low coordination numbers in specific geometries. We previously reported that the homoleptic near-linear Sm complex [Sm{N(SiPr)}] () is oxidized by the 2,2,6,6-tetramethylpiperidinyl-1-oxy (TEMPO) radical to give the heteroleptic, approximately trigonal planar Sm complex, [Sm{N(SiPr)}(TEMPO)] (). Here, we report the synthesis of homologous [Ln{N(SiPr)}(TEMPO)] (; Ln = Tm, Yb) complexes by the oxidation of the parent [Ln{N(SiPr)}] (; Ln = Tm, Yb) with TEMPO; complexes all contain TEMPO anions.

Physico-chemical properties of waste derived biochar from community scale faecal sludge treatment plants.

: The dumping of untreated faecal sludge from non-sewered onsite sanitation facilities causes environmental pollution and exacerbates poor public health outcomes across developing nations. Long-term mechanisms to treat faecal sludge generated from these facilities are needed to resolve the global sanitation crisis and realize the Sustainable Development Goal (SDG) 6 "ensure availability and sustainable management of water and sanitation for all" by 2030.  Pyrolysis of faecal sludge removes pathogens and generates biochar, which can be used as a soil enhancer.

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

We conducted a phase IIa, multi-centre, open label, single arm study (RADICAL; NCT01791985) of AZD4547 (a potent and selective inhibitor of Fibroblast Growth Factor Receptor (FGFR)-1, 2 and 3 receptor tyrosine kinases) administered with anastrozole or letrozole in estrogen receptor positive metastatic breast cancer patients who had become resistant to aromatase inhibitors. After a safety run-in study to assess safety and tolerability, we recruited 52 patients. The primary endpoint was change in tumour size at 12 weeks, and secondary endpoints were to assess response at 6 weeks, 20 weeks and every 8 weeks thereafter and tolerability of the combined treatment.